Seaport Therapeutics Financial Statements
NASDAQ: SPTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.15+0.24 (+1.34%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Seaport Therapeutics has no annual income statement on file yet, so quarterly figures are shown instead.
Seaport Therapeutics revenue and earnings
Seaport Therapeutics reported a net loss of $62.6 million. Diluted earnings per share came in at -$1.78.
Summary generated from market data by MetaCap's automated system. Methodology
Seaport Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Operating Expenses | 65.81M | 27.54M | 18.47M | 16.18M |
| Research & Development | 24.62M | 21.43M | 13.41M | 10.53M |
| Operating Income | -65.81M | -27.54M | -18.47M | -16.18M |
| Other Income (Expense) | 3.46M | 2.65M | 3.53M | 3.09M |
| Pretax Income | -62.35M | -24.89M | -14.94M | -13.09M |
| Income Tax | 251.00K | 519.00K | 134.00K | 31.00K |
| Net Income | -62.60M | -25.41M | -15.08M | -13.13M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -1.78 | -10.34 | -6.40 | -5.65 |
| EPS (Diluted) | -1.78 | -10.34 | -6.40 | -5.65 |
| Shares Outstanding (Basic) | 35.24M | 2.46M | 2.36M | 2.32M |
| Shares Outstanding (Diluted) | 35.24M | 2.46M | 2.36M | 2.32M |
| EBITDA | -65.78M | -27.52M | -18.43M | -16.15M |
This table shows 4 quarterly periods of Seaport Therapeutics's income statement, from Q2 2026 back to Q? 2025, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow SPTX's reporting calendar. What is a income statement?